Triple Negative Breast Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | HiberCell, Inc

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Triple Negative Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years. 
• Triple Negative Breast Cancer companies working in the treatment market are ModernaTX, Inc, OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, G1 Therapeutics, HiberCell, Sanofi/X4 Pharmaceuticals, Phoenix Molecular Designs, and others, are developing therapies for the Triple Negative Breast Cancer treatment 

• Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, Imprime PGG, IPI-549, Trilaciclib, HLX10, Camrelizumab, Trilaciclib, Odetiglucan, Mavorixafor, PMD-026, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years. 
• In June 2023, TOUCH, The American Association for Cancer Research (AACR), Nueva Vida, the Triple Negative Breast Cancer Foundation, and the Black Breast Cancer Alliance received the first Gilead Sciences grant titled “Towards Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” for their project Black TNBC Matters.
• In May 2023, The National Medical Products Administration has approved Shanghai Junshi Biosciences Co., Ltd’s anti-PD-1 monoclonal antibody toripalimab’s supplemental new drug application (“sNDA”) for the treatment of PD-L1 positive (CPS 1) untreated metastatic or recurrent metastatic triple-negative breast cancer when combined with albumin-bound paclitaxel.
• In May 2023, Bliss Biopharmaceutical (Hangzhou) Co., Ltd. and Eisai Co., Ltd. have engaged into a joint development agreement for BB-1701, an antibody-drug conjugate (ADC) with option rights for strategic collaboration. According to the terms of the joint development agreement, Eisai will give BlissBio option rights to develop and market BB-1701 outside of Greater China (China, Hong Kong, Macau, Taiwan) and pay upfront and development milestone payments to BlissBio. Eisai will also conduct a Phase II clinical trial for breast cancer.
• In May 2023, In order to utilise gamma-delta T cells (gdTc) for the treatment of acute myeloid leukaemia (AML) and breast cancer, CytoMed Therapeutics Limited announced that it had entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Centre (“MD Anderson”) in Houston, Texas. This partnership seeks to create novel, cost-effective therapeutic options for people with AML and breast cancer whose requirements have not yet been satisfied.
• In March 2023, An oral, first-in-class small molecule inhibitor of KIF18A developed by Amgen, sovilnesib (AMG650), has been fully licenced by Volastra Therapeutics. The business also completed a $60 million Series A funding. In accordance with the terms of the licencing agreement, Volastra is granted a sole global licence (excluding China) to create and market sovilnesib. Amgen is compensated through a combination of upfront cash and stock as well as royalties and downstream milestone payments. For the treatment of triple-negative breast cancer, high-grade serous ovarian cancer, and other solid tumours with TP53 mutations, the medication is now in Phase 1.
• In February 2023, According to topline results from an interim analysis of the phase 3 TORCHLIGHT trial (NCT04085276), Junshi Biosciences reported that Toripalimab plus nab-paclitaxel demonstrated a significant improvement in progression-free survival (PFS) compared with placebo and nab-paclitaxel in PD-L1-positive patients with stage IV or recurrent/metastatic triple-negative breast cancer (TNBC). In addition, regardless of PD-L1 status, researchers identified a good trend towards enhanced overall survival (OS), a crucial secondary end criterion, with the combination. Toripalimab’s safety profile was comparable with that of its known profile, and no novel signals were noted.
• In March 2023, Results of FUTURE, a phase II umbrella trial examining whether a subtyping-based approach might enhance outcomes for patients with metastatic TNBC, were released. Seven parallel arms included 141 patients with an average of three prior courses of therapy for metastatic disease.
• In June 2021, ‘A Multicenter, Open, Randomized Controlled Study of Camrelizumab+ Nab-paclitaxel + Carboplatin Versus Nab-paclitaxel + Carboplatin as NeoadjuvantTherapy for Triple Negative Breast Cancer (TNBC)’ was started by Jiangsu HengRui Medicine Co., Ltd. 

Triple Negative Breast Cancer Overview

Immunohistochemistry (IHC) is used to determine whether HER2 is overexpressed in a tumour, and fluorescence in situ hybridization (FISH) is used to determine whether its gene is amplified in the case of TNBC, which is defined as a tumour where both ER and PR (oestrogen and progesterone) are negative.

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• mRNA-2752: ModernaTX, Inc
• OTS167PO: OncoTherapy Science
• PMD-026: Phoenix Molecular Designs
• X4P-001: Abbisko Therapeutics
• BLEX 404: BioLite, Inc.
• ZEN003694 +Talazoparib: Zenith Epigenetics
• Imprime PGG: HiberCell, Inc.
• IPI-549: Infinity Pharmaceuticals
• Trilaciclib: G1 Therapeutics, Inc
• HLX10: Shanghai Henlius Biotech
• Camrelizumab: Jiangsu HengRui Medicine
• Trilaciclib: G1 Therapeutics
• Odetiglucan: HiberCell
• Mavorixafor: Sanofi/X4 Pharmaceuticals

Triple Negative Breast Cancer Route of Administration

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Triple Negative Breast Cancer Molecule Type

Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Triple Negative Breast Cancer Pipeline Therapeutics Assessment

• Triple Negative Breast Cancer Assessment by Product Type
• Triple Negative Breast Cancer By Stage and Product Type
• Triple Negative Breast Cancer Assessment by Route of Administration
• Triple Negative Breast Cancer By Stage and Route of Administration
• Triple Negative Breast Cancer Assessment by Molecule Type
• Triple Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for Triple Negative Breast Cancer are – Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc.,  CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

Triple Negative Breast Cancer Pipeline Analysis:

The Triple Negative Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
• Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies

Triple Negative Breast Cancer Pipeline Market Drivers

• Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

Triple Negative Breast Cancer Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

Scope of Triple Negative Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Triple Negative Breast Cancer Companies: ModernaTX, Inc, OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, G1 Therapeutics, HiberCell, Sanofi/X4 Pharmaceuticals, Phoenix Molecular Designs, and others
• Key Triple Negative Breast Cancer Therapies: mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, Imprime PGG, IPI-549, Trilaciclib, HLX10, Camrelizumab, Trilaciclib, Odetiglucan, Mavorixafor, PMD-026, and others
• Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers 

Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Triple Negative Breast Cancer Report Introduction

2. Triple Negative Breast Cancer Executive Summary

3. Triple Negative Breast Cancer Overview

4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Triple Negative Breast Cancer Pipeline Therapeutics

6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)

7. Triple Negative Breast Cancer Mid Stage Products (Phase II)

8. Triple Negative Breast Cancer Early Stage Products (Phase I)

9. Triple Negative Breast Cancer Preclinical Stage Products

10. Triple Negative Breast Cancer Therapeutics Assessment

11. Triple Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Triple Negative Breast Cancer Key Companies

14. Triple Negative Breast Cancer Key Products

15. Triple Negative Breast Cancer Unmet Needs

16 . Triple Negative Breast Cancer Market Drivers and Barriers

17. Triple Negative Breast Cancer Future Perspectives and Conclusion

18. Triple Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services